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ABSTRACT
Objectives Chlamydia trachomatis is the most
common bacterial sexually transmitted infection and is
frequently asymptomatic; ocular C. trachomatis strains
cause trachoma. Mass drug administration (MDA) of
azithromycin for trachoma might also reduce the
prevalence of genital C. trachomatis. In a survey
conducted in the Solomon Islands in 2014, prior to
MDA, the prevalence of genital C. trachomatis was
20.3% (95% CI 15.9% to 25.4%). We conducted a
survey to establish the impact of MDA with azithromycin
on genital C. trachomatis.
Methods Women attending three community
outpatient clinics, predominantly for antenatal care,
10 months after MDA with azithromycin given for
trachoma elimination, were enrolled in this survey. Self-
taken high vaginal swabs were for C. trachomatis and
Neisseria gonorrhoeae using the BD Probetec strand
displacement assay.
Results 298 women were enrolled. C. trachomatis
infection was diagnosed in 43 women (14.4%, 95% CI
10.6% to 18.9%) and N. gonorrhoeae in 9 (3%, 95%
CI 1.4% to 5.7%). The age-adjusted OR for C.
trachomatis infection was consistent with a signiﬁcant
decrease in the prevalence of C. trachomatis following
MDA (OR 0.58, 95% CI 0.37 to 0.94, p=0.027). There
was no change in the prevalence of N. gonorrhoeae
between following MDA (OR 0.51, 95% CI 0.22 to
1.22, p=0.13).
Conclusions This study demonstrated a 40% reduction
in the age-adjusted prevalence of genital C. trachomatis
infection following azithromycin MDA for trachoma
elimination.
BACKGROUND
Sexually transmitted infections (STIs) remain a
major public health problem and their prevalence is
particularly high in resource-limited settings.
Worldwide, Chlamydia trachomatis and Neisseria
gonorrhoeae are the most common bacterial STIs;1
they may lead to infertility, adverse pregnancy out-
comes and an increased risk of HIV transmission.2–4
Infection with C. trachomatis is frequently asymp-
tomatic. In some high-income countries, routine
screening of high-risk groups is encouraged in order
to detect C. trachomatis infection, but screening is
not available where resources are more limited.
Mass treatment has been advocated for STI control
in high-risk groups in low-income and
middle-income countries,5 but few studies have
evaluated its long-term impact.
The prevalence of bacterial STIs is extremely
high in the Western Paciﬁc Region.6–9 In clinic
based studies conducted in Papua New Guinea, the
Solomon Islands and New Caledonia, the preva-
lence of C. trachomatis was estimated to be 11.1%,
20% and 9%, respectively, and the prevalence of
N. gonorrhoeae was 9.7%, 5.1% and 3.5%, respect-
ively. In a community based survey in Samoa, the
prevalence of C. trachomatis was 36%.8
These studies demonstrate that STIs are a major
public health challenge in the Paciﬁc region;
innovative strategies are needed to tackle this epi-
demic.10 Some authors have suggested that, given
the extremely high prevalence of infection,
population-based mass treatment with azithromycin
should be considered as a strategy,8 but there are
limited data to support such an approach.
The Solomon Islands is an archipelago of
approximately 1000 islands, located between
Papua New Guinea and Vanuatu. It has a popula-
tion of approximately 500 000.11 In a study con-
ducted in 2014, we found the prevalence of
genital C. trachomatis to be 20% among women
attending clinics in the capital and this rose to
30% in women aged under 30 years. The
Solomon Islands are also endemic for trachoma, a
blinding eye disease caused by infection with
ocular strains of C. trachomatis.12 Mass drug
administration (MDA) to the entire population,
irrespective of age or gender, of oral azithromycin
(20 mg/kg, to a maximum of 1 g in adults) forms
the cornerstone of the WHO SAFE strategy for
the elimination of trachoma13 and might be antici-
pated to also clear genital C. trachomatis infec-
tions. The Solomon Islands recently undertook
countrywide azithromycin MDA for the purposes
of trachoma control, completing the ﬁrst round in
Honiara in September 2014. Following the same
methods in the same locations as we used in a
pre-MDA survey of STI prevalence,6 we conducted
a repeat survey of women attending outpatient
clinics in Honiara, Solomon Islands approximately
10 months following the MDA to explore any col-
lateral impact on genital infection with C.
trachomatis.
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METHODOLOGY
Primary healthcare to the population of Honiara is generally
provided by nurse-led clinics that offer a full range of outpatient
services, including general medicine, antenatal care and screen-
ing for STIs. All services are free at the point of delivery.
Study population
We used the same methodology for the survey as in our
pre-MDA survey.6 All women aged 16–49 years attending three
public outpatient clinics in Honiara during a 5-day period in
July 2015 were invited to participate in the present survey.
Clinic attendees were predominantly presenting for antenatal
care. Nursing staff ﬂuent in local dialects explained the study
and obtained written informed consent. We did not collect
detailed information on the three individuals who declined to
participate in the study.
With women who gave written, informed consent to partici-
pate, study staff completed a brief questionnaire, including
information on the participant’s age, marital status, previous
treatment for STIs, the presence or absence of current symp-
toms consistent with an STI and whether the participant had
received azithromycin as part of the Ministry of Health and
Medical Services’ trachoma elimination campaign. Women were
then asked to self-collect two high-vaginal swab samples. Both
swabs were collected according to kit manufacturer’s guidelines.
The ﬁrst swab (intended for primary diagnostic purposes) was
transferred to the National Referral Hospital (NRH) on the day
of collection. The second swab was frozen in a dry cryotube on
the same day for future analysis. As the purpose of the study
was to examine the impact of azithromycin MDA on genital C.
trachomatis, samples for HIV or syphilis were not collected
unless these were indicated, according to local protocols, as part
of the patient’s routine clinic care.
Laboratory testing
First swabs were tested within 24 h of collection at the NRH,
using the BD Probetec strand displacement ampliﬁcation assay
(Beckton Dickinson, Franklin Lakes, New Jersey, USA) for the
simultaneous detection of C. trachomatis and N. gonorrhoeae
DNA, according to manufacturer’s guidelines. Positive and nega-
tive controls were included in each diagnostic run.
Patient management
Patients were contacted with their test result by local clinical
staff. Treatment was provided as indicated, in line with Ministry
of Health and Medical Services guidelines for the management
of STIs, which recommend azithromycin for the treatment of C.
trachomatis and a third generation cephalosporin for the treat-
ment of N. gonorrhoeae.14 Contact tracing of partners with a
positive test result was conducted in line with national guidelines.
Sample size
We calculated that a sample size of 200 women was required to
have 80% power to show that the prevalence of C. trachomatis
was ≤10% in the post-MDA sample, as compared with 20% in
the pre-MDA sample.6 As this was a before-and-after study, we
also calculated the sample size required to show a signiﬁcant dif-
ference between women who reported having received and not
having received azithromycin during MDA. On the assumption
that the C. trachomatis prevalence would be unchanged in
women who reported not having received MDA (20%) and that
it would have declined to 5% in women who were treated
during MDA, we calculated that a sample of 75 women who
had not received azithromycin during the MDA campaign
would be required to show a signiﬁcant difference between the
groups. With a trachoma-programme-estimated MDA coverage
of between 75% and 80% we calculated that we would need to
recruit approximately 300 women in total.
Statistical analysis
We report prevalence of STIs stratiﬁed by age (16–29 years vs
30–49 years). Exact CIs based on the binomial distribution were
calculated for each prevalence estimate. Direct standardisation
was used to calculate age-speciﬁc prevalence estimates based on
the age distribution in the Solomon Islands census.11 We used
logistic regression to compare the prevalence of STIs both
between the pre-MDA and post-MDA surveys after controlling
for confounders (age, education, clinic, whether the individual
was currently living with a spouse/partner), and between partici-
pants in the post-MDA survey who did and did not report
receiving treatment during MDA. Logistic regression was also
used to estimate unadjusted and adjusted ORs for factors asso-
ciated with infection, including demographic variables, symp-
toms of an STI or recent treatment for an STI, and treatment as
part of the Ministry of Health trachoma elimination pro-
gramme. Patients reporting dyspareunia, abnormal vaginal dis-
charge or a genital ulcer in the last month were considered to
have symptoms consistent with an STI. All analyses were con-
ducted using Stata V.13.1 (STATACorp, Texas, USA).
RESULTS
Three hundred and one women were seen at the clinics on study
days, of whom 298 (99%) were recruited to this study. Three
patients declined to participate. The median age of participants
was 25 years (IQR 21–30 years) and the median number of years
of education was 9 years (IQR 6–12 years). No women had specif-
ically sought care for current symptoms of an STI but on system-
atic questioning 23 (7.7%) reported current symptoms consistent
with an STI. Twenty-four of 295 women (8.1%) reported treat-
ment for an STI within the previous 12 months. Study partici-
pants recruited in the post-MDA survey were slightly younger and
slightly more educated than those recruited in the pre-MDA
survey (p<0.01 for both comparisons) and slightly more likely to
be living with their partner/spouse (p=0.037) (table 1). Only
142/295 women (48.1%) reported having been treated with azi-
thromycin as part of the trachoma campaign. Age and level of
education did not differ signiﬁcantly between women who did
and did not report receiving azithromycinMDA (data not shown).
Diagnostic test results
In the post-MDA survey C. trachomatis infection was diagnosed
in 43 women (14.4%, 95% CI 10.6% to 18.9%) and N. gonor-
rhoeae in 9 (3%, 95% CI 1.4% to 5.7%). The prevalence of C.
trachomatis was signiﬁcantly higher in women aged under
30 years than in those aged 30–49 years (17.7% vs 5.1%,
p=0.007) and the prevalence of N. gonorrhoeae was also higher
in women aged under 30 years than in their older peers,
although the latter difference was not statistically signiﬁcant
(3.6% vs 1.3%, p=0.297) (table 2). There was no signiﬁcant
association between a positive diagnostic test for an STI and
education level, marital status, living with a partner, current
symptoms of an STI or reporting recent treatment for an STI.
In the combined data set (pre-MDA and post-MDA surveys)
only age under 30 years (OR 3.55, 95% CI 1.94 to 6.5,
p<0.0001) and not currently living with a partner were asso-
ciated with a positive test result for C. trachomatis (OR 1.74,
95% CI 1.0 to 2.9, p=0.044).
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Impact of MDA on prevalence of bacterial STI
The unadjusted prevalence of C. trachomatis had not changed
signiﬁcantly from the pre-MDA survey (14.4% vs 20.3%,
p=0.058) (table 3). The age-adjusted prevalence estimate of C.
trachomatis was 20.7% in the pre-MDA survey and 12.5% in
the post-MDA survey (p=0.0073) (table 4). After adjusting for
confounders women in the post-MDA survey were signiﬁcantly
less likely to have a positive test result for C. trachomatis com-
pared with women in the pre-MDA survey (OR 0.52, 95% CI
0.32 to 0.85, p=0.009). Among study participants in the
post-MDA survey, the prevalence of C. trachomatis was lower in
those who reported receiving treatment during the MDA cam-
paign, but this difference was not statistically signiﬁcant (11.3%
vs 17.8%, p=0.12).
Neither the unadjusted prevalence of N. gonorrhoeae (5.1%
vs 3.0%, p=0.20) nor the age-adjusted prevalence (5.3% vs
3.1%, p=0.18) had changed signiﬁcantly between the pre-MDA
and post-MDA surveys, and this remained true after adjusting
for confounders (OR 0.57, 95% CI 0.23 to 1.39, p=0.22)
(tables 3 and 4). In the post-MDA survey, the difference in the
prevalence of N. gonorrhoeae between individuals who did and
did not report receiving azithromycin during MDA was not stat-
istically signiﬁcant (4.9% vs 1.3%, p=0.07).
DISCUSSION
Key results
In this study we found a 40% decrease in the prevalence of
genital C. trachomatis infection among female clinic attenders
10 months after azithromycin MDA conducted for the purpose
of trachoma elimination. Although the unadjusted decrease in
prevalence of C. trachomatis was not statistically signiﬁcant,
women enrolled in the post-MDA survey were signiﬁcantly
younger than those in the pre-MDA survey and, after control-
ling for age, there was strong evidence of a signiﬁcant decrease
in the prevalence of genital C. trachomatis infection.
A single round of azithromycin MDA can have a profound and
sustained impact on the prevalence of ocular C. trachomatis
infection.15 16 Presumptive mass treatment of sex workers has
been shown to reduce the prevalence of STIs among sex workers
and their clients in the short term in several studies,17–19 but only
two published studies have measured its impact in the general
population. Studies in Greenland in the 1960s demonstrated a
signiﬁcant impact on gonorrhoea among 15–30 year olds when
MDA was combined with clinical examination, laboratory diag-
nosis and contact tracing but not from MDA alonee.20 In the
Rakai district of Uganda, ﬁve pairs of communities were rando-
mised to receive MDA for either STIs or helminth infection
every 10 months.21 Treatment coverage was estimated to be
between 70% and 80% at each treatment round. At the
20 month follow-up, the prevalence of both syphilis and tricho-
moniasis was signiﬁcantly lower in the intervention arm. There
was no signiﬁcant difference between arms in the prevalence of
C. trachomatis or N. gonorrhoeae at 20 months, although the
prevalence of C. trachomatis fell signiﬁcantly in the intervention
arm from baseline (4.0%) to 20 months (2.4%, p<0.01), having
marginally increased in the control arm from 2.2% to 2.6%
during the same period.21
The signiﬁcant decrease in C. trachomatis prevalence seen in
this study 10 months after MDA is encouraging, and suggests
that this may be a particularly useful strategy in island popula-
tions such as this, where population mobility is likely to be
lower than in other settings. The extremely high prevalence of
C. trachomatis at baseline, compared with most settings, may
have increased our ability to detect a signiﬁcant drop in the
prevalence of infection. With data from only one post-MDA
time point we cannot exclude the possibility that there was a
more profound decrease in the prevalence of genital C. tracho-
matis immediately following MDA, but that this had begun to
return to pretreatment levels by the time our impact assessment
was conducted. More regular follow-up surveys post MDA
should be considered in future studies to better explore the
Table 2 Prevalence of sexually transmitted infections by age
group in post-MDA survey
Overall (n=298)
Age 16–29
years (n=220)
Age 30–49
years (n=78)
Chlamydia
trachomatis
n=43
14.4% (10.6%
to18.9%)
n=39
17.7% (12.9% to
23.4%)
n=4
5.1% (1.4% to
12.6%)
Neisseria
gonorrhoeae
n=9
3.0% (95% CI
1.4% to 5.7%)
n=8
3.6% (1.6% to
7.0%)
n=1
1.3% (0.3% to
6.9%)
MDA, mass drug administration.
Table 3 Prevalence of sexually transmitted infections in the
pre-MDA and post-MDA surveys
Post-MDA survey
% (95% CI)
Pre-MDA
survey
(n=296)
% (95%
CI)
Overall
(n=298)*
Reported
receiving
treatment
during MDA
(n=142)
Reported not
receiving
treatment
during MDA
(n=152)
Chlamydia
trachomatis
n=60
20.3%
(15.9% to
25.4%)
n=43
14.4%
(10.6% to
18.9%)
n=16
11.3% (6.6% to
17.7%)
n=27
17.8% (12.0%
to 24.8%)
Neisseria
gonorrhoeae
n=15
5.1% (2.9%
to 8.2%)
n=9
3.0%
(1.4% to
5.7%)
n=7
4.9% (2.0% to
9.9%)
n=2
1.3% (0.16% to
4.7%)
*Four participants in the post-MDA survey were not sure if they had received MDA or
not.
MDA, mass drug administration.
Table 1 Demographic characteristics of study participants
Pre-MDA survey
n=296
Post-MDA survey
n=298
Age (median and IQR) (years) 28 (23–33) 25 (21–30)
Formal education (median and
IQR) (years)
8 (5–11) 9 (6–12)
Ethnicity (%)
Melanesian 93.8 89.5
Polynesian 3.8 6.8
Micronesian 2.1 2.0
Other 0.4 1
Marital status (%)
Married 82.4 78.4
Unmarried 17.6 21.6
Currently living with spouse/
partner
88.8 87.2
MDA, mass drug administration.
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impact of the intervention. If a signiﬁcant effect is conﬁrmed, it
will be important to explore the idea that the optimal MDA fre-
quency for control of genital C. trachomatis could differ from
the annual rounds recommended for trachoma elimination.
Limitations
Although the impact on the prevalence of genital C. trachomatis
is encouraging, MDA with azithromycin might potentially
induce antimicrobial resistance in other organisms including N.
gonorrhoeae and Mycoplasma genitalium.22 Unfortunately
laboratory facilities to perform gonococcal culture or testing for
M. genitalium are not available in the Solomon Islands. Future
work, using additional molecular diagnostics not available in the
country, is planned using the duplicate swabs collected from
study participants during this study, which may allow a prelimin-
ary exploration of these questions.
Our study has some weaknesses, the most notable of which is
the convenience sampling method. To fully assess the impact of
an azithromycin MDA round, a random population sampling
design would provide additional useful data. In the Solomon
Islands, however, discussion of sexual behaviours remains rela-
tively taboo, and random sampling for a sexual health survey
would be unlikely to produce a representative group of study
participants. A convenience sample has been used in each of the
three previous surveys conducted here. Although the current
report describes the ‘after’ component of a before-and-after
study, the previous three surveys suggested a steady increase in
the prevalence of genital C. trachomatis infection among female
clinic attenders, from 8% in 2004 to 16% in 2008, rising again
to 20% in 2014.10 23 Our post-MDA study is the ﬁrst to show a
downward step, which may be taken as further evidence sup-
porting the veracity of the effect we report. Although we cannot
exclude a secular trend between our pre-MDA and post-MDA
surveys, it seems unlikely that these would account for the sig-
niﬁcant decrease in the prevalence of genital C. trachomatis that
we observed.
Second, we lacked an objective measure of treatment uptake
during the MDA campaign, so relied on patient report, which is
likely to be subject to recall bias.24 Unfortunately it was not pos-
sible to identify study participants within the routine treatment
records produced during MDA. We also lacked information on
whether patients’ regular sexual partner(s) had been treated
during the MDA campaign, which may partially confound our
ﬁndings.
Interpretation
STIs remain a major public health problem in the Paciﬁc, and
improved strategies for dealing with this ongoing epidemic are
required. The reduction in prevalence of genital C. trachomatis
infection following MDA for trachoma seen in this study sug-
gests that azithromycin MDA may be one such strategy. Current
approaches to syndromic management miss many cases of bac-
terial STIs.25 Other suggested population-based interventions
include attempts to increase the coverage of screening for C. tra-
chomatis and behavioural interventions to reduce high-risk
sexual behaviour, but these are complex and expensive pro-
grammes, which have had variable success in reducing the
prevalence of STIs.26 27 Azithromycin MDA is a well established
and safe intervention which has been successfully conducted in
a wide range of settings.13 28 Prospective evaluations of commu-
nity mass treatment strategies speciﬁcally targeting sexually
transmitted C. trachomatis should be undertaken.
Key messages
▸ Bacterial sexually transmitted infections (STIs) are common
among female clinic attenders in the Solomon Islands.
▸ There was a 40% reduction in the prevalence of genital
Chlamydia infection among this population following a
single round of mass treatment with azithromycin.
▸ Future studies to assess whether community mass treatment
may be a viable strategy to control the epidemic of STIs in
the Paciﬁc should be performed.
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